Table 3.

Clinical and epidemiological data on poliomyelitis cases from which V/W recombinant and cocirculating wild strains were‚ÄČisolated

StrainPatient age (mo)OPV historyaCase classificationbSerologyc
P1P2P3
P2-V/406/80191 TVAPP-R<4512<4
P2-V/553/80241 TVAPP-R<418032
P2-V/598/8025NVVAPP-C190512<4
P2-V/146/81181 TVAPP-C<8256<8
P2-V/057/876NVVAPP-C<435010
P2-V/263/6624NVVAPP-CNKNKNK
P1-W/377/8014NVP1-Epid128<4<4
P1-W/635/805NVP1-Epid<4<4<4
P1-W/639/8051 M1P1-Epid32<4<4
P1-W/640/8051 M1P1-Epid22<4<4
P1-W/728/8030NVP1-Epid32>512>512
P1-W/004/817NVP1-Epid<4<4<4
P1-W/032/819NVP1-Epid6<4<4
P1-W/257/8112NVP1-Epid32<4<4
P1-W/469/81181 TP1-Epid128<4<4
P1-W/086/826NVP1-Epid160<4<4
P1-W/522/8171 TP1-Epid32<4<4
P2-W/078/806NVP2-Epid<4<4<4
P2-W/277/80211 TP2-Epid<4<4<4
P3-W/80/45271 M1P3-Epid128<4<4
P3-W/80/455161 M1P3-Epid256<4<4
  • a Number of doses of trivalent (T) or type 1 monovalent (M1) OPV. NV, nonvaccinated.

  • b VAPP-R, VAPP recipient case; VAPP, VAPP contact case; Epid, epidemic poliomyelitis case with PV type 1 (P1-Epid), type 2 (P2-Epid), or type 3 (P3-Epid).

  • c Reciprocal of the serum dilution neutralizing 100 TCID50 of homotypic PV type 1 (P1), type 2 (P2), and type 3 (P3). NK, not known.